4-hydroxy-3,5-diiodo-trans-cinnamic acid | 56926-77-3

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: 4-hydroxy-3,5-diiodo-trans-cinnamic acid
• 英文别名: 4-Hydroxy-3,5-dijod-trans-zimtsaeure；(E)-3-(4-hydroxy-3,5-diiodophenyl)prop-2-enoic acid
• CAS: 56926-77-3
• 化学式: C₉H₆I₂O₃
• 分子量: 415.954
• InChiKey: WTIKMBSLXNHSGL-OWOJBTEDSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  57.5
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  对羟基苯甲醛 在 盐酸 、 sodium acetate 、 一氯化碘 作用下， 生成 4-hydroxy-3,5-diiodo-trans-cinnamic acid
  参考文献：
  名称：

  Flumazenil abolishes midazolam-induced increase in the work of nasal breathing

  摘要：

  Purpose: To evaluate the effects of midazolam sedation followed by flumazenil antagonism on the work of nasal breathing in normal humans.Methods: We measured minute ventilation through the nasal route, respiratory frequency, nasal resistance (R-n) and the work of nasal breathing under three conditions: awake, during midazolam sedation, and after flumazenil antagonism in eight healthy human subjects. A custom-made, partitioned face mask enabled nasal and oral airflow to be measured separately. To calculate R-n and the work of nasal breathing, nasal mask and oropharyngeal pressure was also measured.Results: Total resistive work spent on the upstream segment of the nasal route per minute (W-n) (J.min(-1)) was greater during midazolam sedation (3.6 +/- 2.9) than while awake (1.6 +/- 0.9) and after flumazenil antagonism (1.7 +/- 0.6), respectively (mean +/- SD) (P < 0.05). Total resistive work spent on the upstream segment of nasal breathing (W-n/V-nE) (J.L-1) increased from 0.31 +/- 0.14 to 0.75 +/- 0.61 after midazolam administration (P < 0.05) and decreased to 0.31 +/- 0.10 after flumazenil. Following midazolam administration, a strong correlation was observed between changes in W-n/V-nE and changes in (R-n r = 0.852, P < 0.0001), whereas there was no correlation between changes in W-n and changes in (R-n = 0.159, P = 0.279).Conclusion: The work of breathing spent on the upstream segment of the nasal route increases during midazolam sedation and returns to baseline after flumazenil antagonism.

  DOI：

  10.1007/bf03019871

文献信息

• BIOABSORBABLE MATERIAL AND DEVICE USING THE SAME TO BE PLACED IN THE LIVING BODY
  申请人：Terumo Kabushiki Kaisha

  公开号：EP2243797A1

  公开（公告）日：2010-10-27

  A bioabsorbable material which is flexible and degradable at a controlled rate, and an in-vivo indwelling device made thereof. The bioabsorbable material is a copolymer composed of an aromatic compound having an α,β-unsaturated carboxylic group and at least one hydroxyl group as substituents on the aromatic ring, and a polycarbonate or a monomer constituting polycarbonate. Alternatively, it is a copolymer composed of, as the first component, an aromatic compound having an α,β-unsaturated carboxylic group and at least one hydroxyl group as substituents on the aromatic ring, as the second component, an aromatic compound having an α,β-unsaturated carboxylic group and at least two hydroxyl groups as substituents on the aromatic ring, and, as the third component, a polycarbonate or a monomer constituting polycarbonate.

  一种生物可吸收材料，它具有柔韧性并能以可控速度降解，以及由它制成的体内留置装置。该生物可吸收材料是一种共聚物，由芳香环上具有一个α，β-不饱和羧基和至少一个羟基作为取代基的芳香族化合物和聚碳酸酯或构成聚碳酸酯的单体组成。或者，它是一种共聚物，其第一组分为芳香环上具有一个 α，β-不饱和羧基和至少一个羟基作为取代基的芳香族化合物，第二组分为芳香环上具有一个 α，β-不饱和羧基和至少两个羟基作为取代基的芳香族化合物，第三组分为聚碳酸酯或构成聚碳酸酯的单体。
• BIOABSORBABLE MATERIAL AND IN-VIVO INDWELLING DEVICE MADE THEREOF
  申请人：Akashi Mitsuru

  公开号：US20110046309A1

  公开（公告）日：2011-02-24

  A bioabsorbable material which is flexible and degradable at a controlled rate, and an in-vivo indwelling device made thereof. The bioabsorbable material is a copolymer composed of an aromatic compound having an α,β-unsaturated carboxylic group and at least one hydroxyl group as substituents on the aromatic ring, and a polycarbonate or a monomer constituting polycarbonate. Alternatively, it is a copolymer composed of, as the first component, an aromatic compound having an α,β-unsaturated carboxylic group and at least one hydroxyl group as substituents on the aromatic ring, as the second component, an aromatic compound having an α,β-unsaturated carboxylic group and at least two hydroxyl groups as substituents on the aromatic ring, and, as the third component, a polycarbonate or a monomer constituting polycarbonate.
• US8222349B2
  申请人：——

  公开号：US8222349B2

  公开（公告）日：2012-07-17
• Flumazenil abolishes midazolam-induced increase in the work of nasal breathing
  作者：Yasuko Kawauchi、Tsutomu Oshima、Yuhji Saitoh、Hidenori Toyooka

  DOI：10.1007/bf03019871

  日期：2000.12

  Purpose: To evaluate the effects of midazolam sedation followed by flumazenil antagonism on the work of nasal breathing in normal humans.Methods: We measured minute ventilation through the nasal route, respiratory frequency, nasal resistance (R-n) and the work of nasal breathing under three conditions: awake, during midazolam sedation, and after flumazenil antagonism in eight healthy human subjects. A custom-made, partitioned face mask enabled nasal and oral airflow to be measured separately. To calculate R-n and the work of nasal breathing, nasal mask and oropharyngeal pressure was also measured.Results: Total resistive work spent on the upstream segment of the nasal route per minute (W-n) (J.min(-1)) was greater during midazolam sedation (3.6 +/- 2.9) than while awake (1.6 +/- 0.9) and after flumazenil antagonism (1.7 +/- 0.6), respectively (mean +/- SD) (P < 0.05). Total resistive work spent on the upstream segment of nasal breathing (W-n/V-nE) (J.L-1) increased from 0.31 +/- 0.14 to 0.75 +/- 0.61 after midazolam administration (P < 0.05) and decreased to 0.31 +/- 0.10 after flumazenil. Following midazolam administration, a strong correlation was observed between changes in W-n/V-nE and changes in (R-n r = 0.852, P < 0.0001), whereas there was no correlation between changes in W-n and changes in (R-n = 0.159, P = 0.279).Conclusion: The work of breathing spent on the upstream segment of the nasal route increases during midazolam sedation and returns to baseline after flumazenil antagonism.